This review highlights the global burden of cardiovascular disease and emphasizes the significant gaps in prescription and adherence to proven secondary prevention therapies, particularly in low- and middle-income countries.
No takes yet. Share an insight, caveat, or question.
CVD burden persists and grows in LMIC despite Western gains; leaves open optimal secondary prevention strategies for resource-limited settings.
Bansilal et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: